statnews.com·Jun 12, 2026
Prometheus has successfully raised $12 billion to develop "artificial general engineers" in biopharma, while Abridge has formed partnerships with Eli Lilly and Nvidia to improve clinical trial recruitment. Additionally, a nonprofit organization has acquired a cancer drug for pediatric leukemia, intending to distribute it for free.
Prometheus' substantial $12 billion capital raise for developing "artificial general engineers" highlights the significant investment and interest in AI's potential to transform biopharma, particularly in areas like clinical trial optimization. For someone tracking AI drug discovery, this indicates a robust and growing field with opportunities for partnerships and innovation in AI-driven healthcare solutions.